Of note, recent studies demonstrated the involvement of NAD+ metabolism in IDH1 mutant cancers [77], suggesting the role of metabolic reprogramming in cancer cell invasion even in IDH-mutant gliomas. The gene discussed is IDH2; the disease is glioma.